Lescol L.P. (Fluvastatin Sodium)

Fluvastatin sodium inhibits the enzyme HMG‑CoA reductase, the rate‑limiting step in hepatic cholesterol synthesis. This decreases intracellular cholesterol, up‑regulates LDL receptors, and enhances clearance of LDL particles from the bloodstream.

The dosage of Lescol L.P. is individualized by the prescribing healthcare professional based on the patient’s cholesterol levels, cardiovascular risk profile, age, renal and hepatic function, and concomitant medications. Patients should follow the prescriber’s instructions.

Safety of fluvastatin during pregnancy or lactation has not been established. It is generally contraindicated in pregnancy and should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their physician.

To place an order, submit an enquiry on the Lescol L.P. product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and required import documentation.

Lescol L.P. (fluvastatin) is a moderate‑intensity statin with a relatively favorable drug‑interaction profile compared with some higher‑potency statins such as atorvastatin or rosuvastatin. Choice of statin depends on the target LDL reduction, patient tolerance, comorbidities and potential interactions.

Lescol L.P. tablets should be stored at temperatures below 25 °C, in the original packaging, protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources.

Lescol L.P. is taken orally, usually once daily with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

The most serious adverse reactions include rhabdomyolysis, severe liver injury, and hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should report unexplained muscle pain, weakness, dark urine, or jaundice promptly to their healthcare provider.

Lescol L.P. should be avoided in patients with active liver disease, unexplained persistent elevations of hepatic transaminases, known hypersensitivity to fluvastatin or any excipients, and in pregnant women unless clearly indicated. Caution is also advised in severe renal impairment.